Vivos Therapeutics, Inc. VVOS
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 34.90% | 70.46% | 3.41% | 75.73% | -5.77% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 34.90% | 70.46% | 3.41% | 75.73% | -5.77% |
| Cost of Revenue | 28.65% | 38.16% | -47.78% | 86.50% | 21.88% |
| Gross Profit | 39.95% | 102.72% | 42.49% | 68.68% | -20.41% |
| SG&A Expenses | 8.98% | 75.62% | 87.60% | 71.47% | 50.14% |
| Depreciation & Amortization | 66.67% | 156.50% | 206.94% | 163.01% | 111.03% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.89% | 69.54% | 56.92% | 77.05% | 44.99% |
| Operating Income | 0.82% | -68.84% | -127.44% | -78.98% | -151.29% |
| Income Before Tax | -10.17% | -100.60% | -145.99% | -106.42% | -159.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.17% | -100.60% | -145.99% | -106.42% | -159.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.34% | -98.81% | -143.86% | -106.42% | -159.74% |
| EBIT | 0.82% | -68.84% | -127.44% | -78.98% | -151.29% |
| EBITDA | 5.37% | -64.69% | -123.14% | -74.07% | -154.55% |
| EPS Basic | 43.81% | -16.77% | -41.95% | -24.56% | 7.71% |
| Normalized Basic EPS | 41.01% | -16.12% | -41.22% | -24.51% | 7.71% |
| EPS Diluted | 43.81% | -16.77% | -41.95% | -24.56% | 7.71% |
| Normalized Diluted EPS | 41.01% | -16.12% | -41.22% | -24.51% | 7.71% |
| Average Basic Shares Outstanding | 94.58% | 70.26% | 71.76% | 65.73% | 181.48% |
| Average Diluted Shares Outstanding | 94.58% | 70.26% | 71.76% | 65.73% | 181.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |